AstraZeneca

US Patent Suit Settled by AstraZeneca

A major US patent row has been settled by AstraZeneca over Nexium with Israel based Teva Pharmaceuticals, on Thursday, which ended up protecting the Anglo-Swedish drug manufacturer's highest selling heartburn drug from immediate generic competition.

Amidst a weaker market for medicine stocks, AstraZenenca shares managed to rise by 1.4%, while Teva fell by 0.2%.

Companies: 
General: 
Region: 

Answers to Queries on Motavizumab Sent by AstraZeneca to FDA

On Thursday, the giant Anglo-Swedish pharmaceutical company, AstraZeneca confirmed that it has sent in answers to all the queries that were raised by the US Food and Drug Administration for its infant lung medicine motavizumab, as the company looks to gain approval for the marketing of the drug across America.

Companies: 

AstraZeneca buys French drug developer Novexel

British drug maker AstraZeneca announced Wednesday that it would acquire French drug developer Novexel in a deal worth $505 million.

Under the deal, AstraZeneca will pay $350 million anti-infection group Novexel's shares and another $80 million for its cash.

The British drug maker will pay further $75 million if specific targets in the development of its drug programs are reached.

Companies: 
General: 

Seroquel XR for Use in Depression Approved by FDA

The US Food and Drug Administration has approved AstraZeneca's drug Seroquel XR for use in adult patients suffering from depression, albeit in small numbers and only if all other treatment drugs have failed to trigger a response, as confirmed by the pharmaceutical company. The agency, however, wants more information and some more tests before it can approve the medicine as a "first-line treatment".

Companies: 
General: 
Region: 

AstraZeneca and Targacept Sign Collaboration and License Agreement

Giant drug manufacturers AstraZeneca and Targacept have joined hands and signed a "collaboration and license agreement" for the development and marketing of TC-5214, Targacept's drug for severe depressive disorder.

TC-5214 has recently successfully completed a Phase IIb clinical test and has been described as a "nicotinic channel blocker" which seeks to treat depression by "modulating the activity of various neuronal nicotinic receptor subtypes".

General: 

Pages

Subscribe to RSS - AstraZeneca